We combine standard pharmacokinetics with an established model of viral replication to predict the outcome of therapy as a function of adherence to the drug regimen. We consider two types of treatment failure: failure to eliminate the wild-type virus, and the emergence of drug-resistant virus. Speci¢cally, we determine the conditions under which resistance dominates as a result of imperfect adherence. We derive this result for both single-and triple-drug therapies, with attention to conditions which favour the emergence of viral strains that are resistant to one or more drugs in a cocktail. Our analysis provides quantitative estimates of the degree of adherence necessary to prevent resistance. We derive results speci¢c to the treatment of human immunode¢ciency virus infection, but emphasize that our method is applicable to a range of viral or other infections treated by chemotherapy.
INTRODUCTION
Imperfect adherence to a prescribed regimen is one of the critical obstacles to successful drug therapy. Maintaining adherence may be particularly di¤cult when the drug regimen is complex or side-e¡ects are severe, as is often the case for current human immunode¢ciency virus (HIV) therapy (Besch 1995; Ickovics & Meisler 1997; Katzenstein 1997; Mehta et al. 1997) .
It is widely acknowledged that lack of adherence facilitates the emergence of drug resistance, but the precise mechanisms and conditions under which this occurs have not been elucidated (for a review, see Levin et al. 1998; Levin & Andreason 1999) . The epidemiology of drug resistance has been well characterized (Austin et al. 1997; Bonhoe¡er et al. 1997a; Davies 1997; Levin et al. 1997; Levy 1997; Levin & Andreason 1999) , as has the emergence of drug resistance within an individual (Nowak et al. 1991 (Nowak et al. , 1997 McLean & Nowak 1992; Frost & McLean 1994; Co¤n 1995; Bonhoe¡er & Nowak 1997; Stilianakis et al. 1997; . Three recent papers have modelled the interaction of changing drug concentrations with the population dynamics of a pathogen (Austin et al. 1998; Kepler & Perelson 1998; Lipsitch & Levin 1998) , examining in detail the conditions necessary for treatment success (Austin et al. 1998) or for the emergence of drug resistance (Kepler & Perelson 1998; Lipsitch & Levin 1998) .
The US Department of Health and Human Services (1999) recently declared that`clari¢cation of the degree of adherence [to HIV therapy] . . . necessary to prevent resistance is urgently needed'. This question has begun to be addressed clinically, and sharp increases in virological failure rates have been correlated with decreasing adherence in prospective studies (Paterson et al. 1999) . We examine this question theoretically, predicting treatment outcome as a function of adherence to a given drug regimen.
DOSE AND EFFECT
Although interpatient variation may be a signi¢cant factor, the average pharmacokinetic parameters of drugs used in HIV therapy are well established in humans. For any given drug, the recommended dosing interval T, the maximum concentration in plasma C max , and the serum half-life T 1=2 may be used to predict the time-course of the drug concentration in plasma, C(t). For a more accurate model, the time to peak t p may also be included. We use these parameters to build a simple model of the plasma time-course of the pharmaceutical, assuming a linear rise in drug concentration from the start of the dosing interval to t p , and a single exponential decay thereafter:
C(t)ˆC
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where wˆlog (2)/T 1=2 . Note that C max must be the maximum concentration achieved in plasma after a number of successive doses, such that the patient is in à steady state' with respect to any gradual accumulation of the drug. This model provides an independent estimate of the trough concentration C(T), and the area under the plasma concentration curve AUC, which can be compared to the known pharmacokinetic parameters as a veri¢cation of the model. A sample plasma time-course for a protease inhibitor is illustrated in ¢gure 1. In this example a new dose of the drug is taken every 8 h and no doses are missed (perfect adherence).
To model imperfect adherence, we let p denote the fraction of the prescribed doses of the drug which are taken. If the drug is taken in a given dosing interval, equation (1) describes the time-course of drug concentration for that interval. If the drug is not taken, the dose decays from its current concentration with half-life T 1=2 .
The level of adherence p re£ects the long-term average of the number of doses taken. Adherence patterns may vary between individuals, commonly including total breaks in drug therapy (drug holidays) over a number of days. While the long-term mean adherence is a good prognostic for the long-term outcome of this dynamical system, we note that di¡erent patterns of adherence, even with the same value of p, may shift the balance in favour of the resistant or wild-type virus. We will return to this issue in the subsequent section.
Unless noted otherwise, we use the same pattern of adherence in each of the simulated examples that follow: the probability of taking a dose at the beginning of each interval is independent of previous history and is constant. Thus, for each new dosing interval the drug is taken with a probability equal to the long-term average adherence p. In this simple Poisson model we do not allow for drugs to be taken at time-points in between the dosing intervals.
Although the concentration of the pharmaceutical in plasma can be described with some accuracy, it is di¤cult to predict the time-course of intracellular concentrations of the drug. While the kinetics of drug entry to the intracellular space (for example to cells in lymph tissue), are almost certainly slower than the uptake in plasma, the egress or metabolism of the drug from the cytoplasm is largely unknown. Nonetheless, we can use the plasma concentration as a rough estimate of the time-course of the drug in the system. By neglecting dispersion and delay as the drug enters the intracellular space, we clearly overestimate the temporal e¡ects of dosing at intervals, and therefore we hope to deduce conservative estimates of the need for adherence. (For a fuller treatment of the e¡ects of spatially distinct compartments, see Kepler & Perelson (1998) ; for a detailed model of the kinetics of drug action, see Austin et al. (1998).) Given this simple model of the time-course of drug concentration and an estimate of the dose^response pro¢le for the drug, we can predict the time-course of the antiviral e¡ect. Here we assume that the inhibition of viral replication s can be described by
where IC 50 is the concentration of drug which inhibits viral replication by 50%. Thus when s º 1 the drug has no e¡ect, while if s º 0 the drug completely inhibits viral replication. Although the relationship between in vitro susceptibility of HIV to antiviral drugs and the in vivo inhibition of viral replication in humans has not been rigorously established, we use the in vitro IC 50 value for each drug to provide an estimate of the in vivo value of s. For a number of antiviral drugs, the increase in IC 50 after the emergence of drug resistance in a viral population has been accurately quanti¢ed. These altered values of IC 50 can therefore be used in equation (2) to compute s for drug-resistant strains. Examples of the dose^response curves predicted for the protease inhibitor nel¢navir, are shown in ¢gure 1. HIV isolates from some patients treated with this drug have shown reduced susceptibility (¢vefold to 93-fold) to nel¢navir in vitro, correlated with one or more mutations in the virus protease gene (for reviews, see Moyle & Gazzard 1996; Hoetelmans et al. 1997; McDonald & Kuritzkes 1997; Jarvis & Faulds 1998) . Figure 1b plots the dose^response curve for drug-sensitive virus (dotted line, IC 50ˆ0 :03 mM), partially resistant virus (dashed line, ¢vefold resistance), and highly resistant virus (solid line, 50-fold resistance). Figure 1c illustrates the e¡ect of s on the basic reproductive ratio of the virus R 0 over time. R 0 , originally described in the ecology and epidemiology literature (Macdonald 1952; Dietz 1975 Dietz , 1976 Yorke et al. 1979; May & Anderson 1979; , is de¢ned as the average number of secondary infected cells arising from one infected cell placed into an entirely susceptible cell population. In this example we see that the basic reproductive ratio of the drug-sensitive virus is held very close to zero, while R 0 for the ¢vefold drug-resistant strain (dashed line) is larger but still less than unity at all times. It is clear that, in this example, ¢vefold drug resistance implies that a single missed dose would allow R 0 to exceed unity for a number of hours. A 50-fold increase in resistance (solid line) allows the basic reproductive ratio of the virus to exceed unity almost continually.
VIRUS DYNAMICS
We use a simple model of virus dynamics (McLean & Nowak 1992; Bonhoe¡er & Nowak 1997) , in which we distinguish between susceptible cells x, cells infected with drug-sensitive virus y 1 , and cells infected with drugresistant virus, y 2 . Let us assume that the susceptible cells are produced at a constant rate l from a pool of precursor cells, and die at rate dx. Susceptible cells become infected at rates s 1 1 xy 1 and s 2 2 xy 2 by sensitive and resistant virus respectively, where 1 and 2 re£ect the infectivity of sensitive and resistant virus strains. We assume that 1 > 2 , that is, the wild-type virus is the most infectious strain in the absence of the drug.
Drug treatment is re£ected in the parameters s 1 (t) and s 2 (t) (between zero and unity), which describe the inhibition of viral infectivity for the sensitive and resistant virus. The degree of inhibition is a function of the drug concentration at each time (equation (2)). Infected cells of both strains die with rate constant a. This yields the following system of ordinary di¡erential equations:
This model has some documented shortcomings (McLean & Nowak 1992; Bonhoe¡er & Nowak 1997a,b) , which the inclusion of further parameters (such as the immune response) may serve to alleviate. We have limited our treatment in this paper to the basic model, but note that results might di¡er, at least quantitatively, if the immune response were included explicitly. We use the model of C(t) described above, for a given degree of adherence p, to compute both s 1 and s 2 as described in equation (2) and illustrated in ¢gure 1. To model the e¡ects of several drugs administered simultaneously, we compute the concentration time-course for each drug and then multiply the value of s computed for each drug to give the total inhibition at each timepoint.
The di¡erential equations described above can be simulated for a given drug regimen and adherence p. Figure 2 shows four examples of the progression of HIV over 18 months, for the same initial conditions but di¡erent degrees or patterns of adherence. Panels on the left plot virus load (number of infected cells) for the sensitive (solid line) and resistant (dotted line) viral strains; panels on the right show the drug concentration for the ¢rst ten days of treatment, which begins at day 30. We see that when pˆ1 (¢gure 2a), the virus is rapidly eliminated from the body, while when pˆ0:3 (¢gure 2d ), treatment fails and the wild-type virus persists. For intermediate values of p (¢gure 2b,c), however, the outcome depends on the adherence pattern. For the Poisson model of adherence, the sensitive virus is eliminated but the drug-resistant virus persists. If dose-taking is slightly more`clumped' than in the Poisson model however, the wild-type virus continues to dominate the population. We will discuss this result further in } 4.
Several interesting observations can be made at this point. Comparing perfect adherence with the Poisson example when pˆ0:5, we note in both cases that immediately after the start of treatment the frequency of the drug-sensitive virus decreases. Because the initial frequency of the drug-resistant mutant is so small (in these examples 1 in 10 7 ), and because the basic reproductive ratio of the drug-sensitive virus is reduced by therapy to be just below that of the drug-resistant strain, there is a lag of more than eight months before the resistant strain begins to dominate the system. Thus, in the ¢rst few months of therapy, the situation when drug levels are adequate to eliminate the virus may be indistinguishable from the situation where an infectious drug-resistant mutant is growing exponentially from a tiny initial frequency, in competition with the wild-type virus, and only gradually dominating the system. Once the drugresistant mutant has arisen, we note further that the total virus load may be nearly indistinguishable from the pretreatment virus load (Bonhoe¡er & Nowak (1997) , but see } 5).
LONG-TERM OUTCOME OF THERAPY (a) Single-drug therapy
We can analytically predict the outcome of therapy for a known adherence, p, and a simple adherence pattern. To do this, we ¢rst consider the variation in s over time, as depicted in ¢gure 1. Because the variation in s is over a time-scale of hours, whereas the ultimate outcome of therapy occurs over the course of months or years, we are interested in the mean value of s, · s( p), when adherence is p. As an example, equation (A3) (derived in Appendix A) approximates the value of · s 1 ( p) and · s 2 ( p) for the drugsensitive and drug-resistant viral strains, respectively, using a Poisson model of adherence.
Using these results, we compute the mean value of the basic reproductive ratio for both the drug-sensitive virus (R 1 ) and drug-resistant virus (R 2 ):
The mean values of these reproductive ratios serve as useful predictors of the long-term outcome of the system under several conditions: (i) the chance extinction of the drug-resistant strain is unlikely (true for HIV);
(ii) the time-scale of consistent dose taking or doses
Adherence and resistance L. M. Wahl and M. A. Nowak 837 missed is short compared to the characteristic times in equations (3)^(5) (thus the question of drug holidays cannot be addressed by our methods at present); and (iii) the variations in R 1 and R 2 are relatively smooth (this is true, for example, when doses decay smoothly and the dose^response curve is described by equation (2)). We note, however, that the long-term average of R 1 and R 2 are not simple functions of p, but also depend on the pattern of dose taking; we address this in ¢gure 3b, described below. For any adherence pattern, we know that 1 > 2 , and so it is clear that when pˆ0 (pre-treatment), R 1 (0)4 R 2 (0). Both R 1 and R 2 will be decreasing functions of p, but R 1 should fall faster as p increases. Thus, we expect that at some threshold value of adherence, the basic reproductive ratio of the drug-resistant virus will be larger than that of the drug-sensitive virus. If R 2 is greater than unity at this point, then the drugresistant virus will experience exponential growth. This result is illustrated in ¢gure 3a, which illustrates both R 1 and R 2 for p between zero and unity. For this example we study a Poisson model of adherence with the protease inhibitor indinavir, which is taken every 8 h and has a 2 h half-life. Phenotypic and genotypic testing of HIV isolates from patients treated with indinavir have shown three or four mutations in the virus protease gene which confer a For this example we simulate the timecourse of the protease inhibitor ritonavir, withT1=2ˆ4 h, Tˆ12 h, Cmaxˆ11:2 mg ml ¡1 and IC50ˆ0:0159 mg ml ¡1 . We assume that 1 in 10 7 infected cells are initially infected with a mutant strain of the virus and that these mutations confer a tenfold resistance to ritonavir. The level of adherence to the drug regimen was varied: pˆ1:0 (a) pˆ0:5 (b,c), and pˆ0:3 (d). Panels on the left illustrate the total number of cells infected by drug-sensitive ( y 1 , solid line) and drug-resistant ( y 2 , dotted line) over 18 months. Panels on the right show the time-course of the drug concentration for the ¢rst ten days of treatment (note the change in time-scale) which begins at day 30. We ¢nd that with intermediate levels of adherence in a Poisson pattern, the drug-resistant strain dominates; this occurs only after some eight months of therapy, and ¢xation requires over 18 months. In (c) we provide an example with the same mean adherence, 0.5, but a`clumped' pattern of dose-taking: every time a dose is taken, two doses are taken, and every time a dose is missed, two doses are missed. This simplistic model illustrates that the speci¢c dose-taking pattern may change therapy outcome; treatment fails in this example. Simulations were performed by integrating equations (3)^(5) numerically with initial conditions x(0)ˆ1000, y 1 (0)ˆ500 and y 2 (0)ˆ5 £ 10 ¡5 ; other parameter values were lˆ100, dˆ0:1, aˆ0:5, 1ˆ0 :008 and 2ˆ0 :004.
four-to eightfold resistance to the drug in vitro (for reviews, see Moyle & Gazzard 1996; Hoetelmans et al. 1997; McDonald & Kuritzkes 1997) .
From ¢gure 3, we see three separate regions of treatment outcome. When p5 0:15, the drug-sensitive virus dominates; treatment fails to eliminate the wild-type virus. For 0:155 p5 0:6, R 2 is larger than R 1 , and R 2 is also larger than unity. In this large region treatment also fails, but it fails because of the emergence of the drugresistant viral strain. Treatment succeeds in eliminating both strains of the virus when p4 0:6. We note further that there are two situations in which resistance dominates. For 0:155 p5 0:45, treatment is insu¤cient to eradicate either viral strain (both R 1 and R 2 are greater than unity), but resistance dominates because the drug suppresses the wild-type virus such that R 2 4 R 1 . In this region treatment would fail even if the drug-resistant mutant did not exist. If the drug-resistant mutant exists, however, it competes with the wild-type virus. The drug-resistant mutant may emerge as the dominant viral strain only gradually in this case, because the di¡erence between R 2 and R 1 is not large (see, for example, ¢gure 2, when pˆ0:3). In contrast, for 0:455 p5 0:6, treatment would be su¤cient to eradicate the wild-type virus if the drug-resistant mutant did not exist, and if the drug-resistant mutant does exist it will dominate the system rapidly.
In ¢gure 3b, we explore the e¡ect of di¡erent dosetaking patterns. As described in Appendix A, we can determine analytically the long-term average of the antiviral e¡ect, · s 1 or · s 2 , for a speci¢ed pattern of adherence. We de¢ne the resistance advantage as the ratio of these quantities, · s 2 = · s 1 . It is clear that for the resistant mutant to out-compete the wild-type, this resistance advantage must exceed the pre-treatment ratio of R 1 =R 2 . We computed the resistance advantage for a pattern of increasingly lengthy dosing`blocks' of n successive doses or missed doses. Every nth dose, Poisson statistics identical to the Poisson model described above are used to determine whether doses will be taken for the following block of time: if a dose is taken, then n doses are taken successively; if a dose is missed, then n doses are missed successively. Thus doses are increasingly`clumped' as the block size increases, while the long-term average adherence p is constant (the same fraction of total doses is taken irrespective of block size).
As illustrated in ¢gure 3, doses which occur in blocks can reduce the advantage of resistance. Intuitively, we argue that resistance thrives under intermediate drug concentrationsöhigh levels of the pharmaceutical reduce viral replication, while low levels do not su¤ciently hinder the wild-type. Thus constraining doses to occur consecutively signi¢cantly decreases the amount of time during which drug concentrations are intermediate and the resistant virus has a replication advantage. This explains the failure to out-compete the wild-type strain illustrated for the`clumped' dosing regimen in ¢gure 2. The derivation of · s 1 and · s 2 for blocks of consistent dosing is provided in Appendix A.
In ¢gure 3a, we set the pre-treatment R 1 (0)ˆ4 and R 2 (0)ˆ3:5. We generalize this result for di¡erent values of the basic reproductive ratios in ¢gure 4. Here each panel shows the regions of treatment failure (hatching and shading) or treatment success (solid white). These regions are plotted for R 1 (0) between unity and ten on the y-axis. Each panel shows the result for R 2 (0) as a di¡erent (but constant) fraction of R 1 (0). The thick black line in each panel shows where R 1 drops below unity. Thus treatment failure will occur in the region to the left of this line (horizontal hatching), regardless of whether the resistant mutant exists. If the resistant mutant exists, it will dominate the system for parameter values shown in Figure 3 . Basic reproductive ratio, adherence and adherence patterns. In (a), we determine R 1 and R 2 as described in equation (6), for 1ˆ0:002, 2ˆ0:00175, lˆ100, dˆ0:1, aˆ0:5. The values of · s( p) are determined as described in equation (A3). In this example we use the Poisson adherence pattern and parameters which approximate the e¡ect of the protease inhibitor indinavir (T 1=2ˆ2 h, Tˆ8 h and Cmaxˆ12:6 mM). For the drug-sensitive strain we set IC 50ˆ5 :3 £ 10 ¡3 mM, while IC 50 for the drug-resistant strain is ten times greater (0.053 mM). For zero adherence (pre-treatment), R14 R2, and the resistant strain will be out-competed. Note that for p5 0:45, treatment will fail to eradicate the virus even if the drug-resistant mutant does not exist (R 1 4 1). For p4 0:6, this model predicts treatment success. For adherence between 0.15 and 0.6, if the resistant mutant exists it will dominate the system. In (b) we use the same parameter values, but doses are taken or missed in blocks of n successive doses, between 8 h and 4 days or 1^24 doses. Here we illustrate the decreasing advantage of resistance ( · s2/ · s1) with increasing block size, for mean adherence ( p) values between 0.2 and 0.9. grey shading, either by out-competing the drug-sensitive virus (grey shading to the left of the black line) or by surviving in a situation where the drug-sensitive virus would be eliminated (grey shading to the right of the black line).
For this example we model the e¡ect of the protease inhibitor ritonavir,which is typically taken every 12 h and has a 4 h half-life, and once again return to the Poisson pattern of adherence. Phenotypic and genotypic testing of HIV isolates from patients treated with ritonavir have shown a number of mutations in the virus protease gene which confer a 2.5-fold to eightfold resistance to the drug in vitro (for reviews, see Lea & Faulds 1996; Moyle & Gazzard 1996; Hoetelmans et al. 1997; McDonald & Kuritzkes 1997) . Figure 4 illustrates a few key points. Note, ¢rst, that when the basic reproductive ratio of the drug-resistant virus is much smaller than the wild-type R 0 , there is no region where resistance can emerge (R 2 4 0:4R 1 ). In this case, increasing adherence moves directly from regions of failure (failure to eliminate y 1 )to treatment success. Likewise, if the basic reproductive ratio of the wild-type virus is small (less than two or three), treatment is successful for very low levels of adherence (anything over p º 0:4), and if treatment fails it is probably due to the persistence of the drug-sensitive virus: resistance is very unlikely to emerge. The critical feature of the system, however, appears to be the ratio of the pre-treatment R 2 to the pretreatment R 1 . If this ratio is higher than about 0.7, and if R 1 is higher than 2 or 3, resistance is very likely to dominate the system after treatment. For many cases even 80% adherence with this single drug will not be su¤cient to eliminate the drug-resistant virus.
(b) Combination therapy
We repeated this analysis for triple-drug therapy, using the standard regimen of two nucleoside analogue reverse transcriptase inhibitors (3TC and AZT) and a single protease inhibitor (ritonavir). Phenotypic studies have shown HIV isolates with over 500-fold resistance to 3TC; this resistance emerges rapidly, in weeks to months (Schuurman et al. 1995; Mayers 1996) . For AZT, mutations typically emerge over months or years and may confer up to 100-fold resistance (Richman et al. 1994; de Jong et al. 1996; Mayers 1996) . For the results presented below, we assumed that the viral strains resistant to 3TC have a 200-fold resistance, those strains resistant to AZT have a 100-fold resistance, and those resistant to ritonavir have a tenfold resistance.
We de¢ne the dosing interval and time-course separately for each drug, modelling the fraction of doses taken independently for each one, but combining the e¡ects of all three drugs as described above when computing R 1 . We then compute R i at each time for a number of possible drug-resistant strains, y i . In this example we consider a total of seven drug-resistant strains: three that are only Figure 4 . Therapy outcome as a function of adherence for a single drug regimen. Therapy outcome is illustrated as a function of adherence, ( p, x-axis) , the basic reproductive ratio of the drug-sensitive virus (R 1 , y-axis) and the ratio of R 1 to R 2 (panels). The solid black line in each panel shows the degree of adherence at which R1ˆ1. In regions to the left of this line, treatment will fail to eliminate the drug-sensitive virus (horizontal hatching). The grey region in each ¢gure shows parameter values for which the resistant mutant will dominate the system, either by out-competing the drug-sensitive virus (to the left of the solid line, R24 R14 1), or by surviving in a situation where the wild-type virus cannot survive (to the right of the line, R24 14 R1). Thus regions to the right of the solid line show parameter values for which the emergence of resistant virus will cause treatment failure, for a drug regimen and adherence that would be su¤cient to eliminate the wild-type alone. We use parameters which approximate the e¡ect of the protease inhibitor ritonavir (T 1=2ˆ4 h, Tˆ12 h and C maxˆ1 1:2 mg ml ¡1 ). For the drug-sensitive strain we set IC 50ˆ0 :0159 mg ml ¡1 , while IC 50 for the drug-resistant strain is ten times greater (0.159 mg ml ¡1 ).
resistant to one of the three drugs, three that are resistant to two of the three drugs, and one that is resistant to all three drugs in the cocktail. For simplicity we have assumed that all the drug-resistant strains have the same infectivity ( 2 ), which is less than the infectivity of the wild-type. We have neglected cross-resistance (resistance to one drug does not confer any advantage when facing the other drugs), and have also ignored possible drugd rug interactions, which may alter the concentration time-course when antivirals are taken in combination.
The results of this analysis appear in ¢gure 5, for two di¡erent ratios of wild-type and resistant infectivities. As in ¢gure 4, the region to the left of the thick black line (horizontal hatching in both panels) corresponds to treatment failureöthe wild-type virus is not eliminated by the drug, regardless of whether resistant virus stains are present. The white region on the right of both panels corresponds to treatment success. Considering ¢gure 5b ¢rst, for the case when the drug-resistant mutants are only slightly less infective than the wild-type, the central regions can be described as follows.
Suppose that resistant mutants exist which are resistant to one of the three drugs, but no resistant strains that are resistant to several drugs exist. Resistance will then arise in the large dark grey region in the centre of the plot. To the left of that region treatment fails by failing to eliminate y 1 , while to the right of that region treatment succeeds.
If, however, mutants exist which are resistant to one or two drugs, resistance will arise over a larger area. Anywhere within the middle grey region or dark grey central region of the graph, a mutant which is resistant to two of the three drugs will dominate. Finally, if mutants exist which are resistant to all three drugs, they will dominate anywhere within the light grey, middle grey or dark grey central regions.
In ¢gure 3a we see that if the pre-treatment cost of resistance is su¤ciently high, treatment is likely either to fail (to eliminate the wild-type virus) or to succeed; parameter values for which resistant mutants are predicted to arise and dominate the system are rare. We note, however, that once resistance has emerged during therapy the viral load does not necessarily re£ect this pre-treatment cost of resistance (see } 5).
We see from these results that viral strains with multiple resistance are able to dominate the system for higher degrees of adherenceöbut of course these strains are less likely to exist. We also note the increased e¤cacy of triple-drug over single-drug therapy. Treatment is successful over a wider range of adherence levels and resistance of any sort, on the whole, is less likely to emerge. We conclude that triple-drug therapy is more robust to non-adherence than single-drug therapy. Finally, we note that in this example, treatment is most likely to fail by the emergence of a viral strain that is resistant to one of the three drugs.
DISCUSSION
In this system, the basic reproductive ratio rises and falls with drug concentration, as shown in ¢gure 1. This variation occurs over hours, whereas the time-scale of therapy outcome is months or years. Our model predicts that the relevant predictor of therapy outcome is the long-term average of R 0 , which is proportional to the long-term average of the antiviral e¡ect s. This result is in contrast to the intuitive notion that a qualitative change might occur if R 0 becomes brie£y greater than unity when, for example, a dose of the drug is missed. Although each missed dose does have a detrimental e¡ect on the long-term antiviral e¡ect (altering · s signi¢cantly), we ¢nd that the long-term pattern of adherence is more important than whether the virus has been allowed to replicate e¡ectively for short intervals. This suggests the possibility of analysing clinical data by aggregating individuals depending on long-term averages of adherence, despite considerable variation in Figure 5 . Therapy outcome as a function of adherence for triple-drug regimen.Therapy outcome is illustrated as a function of adherence ( p, x-axis) , and the basic reproductive ratio of the drug-sensitive virus (R1, y-axis). Here the ratio of R 2 to R 1 is 0.3 (a) or 0.9 (b). The solid black line shows the degree of adherence at which R1ˆ1. Therapy outcome is as described in the text: in brief, grey regions illustrate regions of treatment failure due to the emergence of viral strains resistant to one, two or three of the drugs. We ¢nd that treatment fails at higher degrees of adherence for multiply resistant viral strains, if these strains exist. We also note that triple-drug therapy is robust to higher levels of non-adherence than single-drug therapy. For this example we used a drug regimen which approximates the combination of 3TC, AZT and ritonavir (drug 1: dose-taking patterns. We emphasize, however, that the long-term antiviral e¡ect may di¡er for di¡erent dosetaking patterns, even though the total adherence (total fraction of doses taken) is the same. Our conclusions do not consider the possibility that the virus population may evolve towards synchronization with the pattern of drug therapy. If the life cycle of the virus is a multiple of the dosing interval, it is possible that over time the bulk of the virus population will replicate during trough concentrations of the drug, when R 0 is highest. This suggests a possibility for future work.
Our model predicts that non-adherence allows resistant strains (which already exist at very low frequencies in the pre-treatment host; Ribeiro et al. 1998) to grow exponentially, dominating the system after some months. The time taken for the resistant mutant to emerge can be very long if the basic reproductive ratios of the sensitive and resistant viral strains are close. Although it is unlikely that successful drug therapy will allow new resistant strains to emerge during treatment (Bonhoe¡er et al. 1997b) , the degree to which this holds for imperfect drug therapy is unclear. Non-adherence may play a key role in the`¢ne-tuning' of resistance over time. Thus, another direction for future study is the e¡ect of adherence on the evolution of gradually more resistant and multiply resistant strains of the virus.
Finally, as discussed more fully in Bonhoe¡er & Nowak (1997) , this basic model of viral dynamics is only able to explain a ten-to 100-fold reduction in virus load during therapy if the basic reproductive ratio of the virus during therapy is very close to unity. While this assumption appears unrealistic, we point out that increasing adherence reduces R 0 for both the resistant and sensitive virus (¢gure 3). Resistance is only able to emerge when the basic reproductive ratio of the drug-sensitive virus falls below unity, while R 0 for the drug-resistant virus is still greater than unity. If the (pre-treatment) infectivities of these two strains are close, it becomes plausible that R 0 for the drug-resistant virus is close to unity when this occurs. The inclusion of an immune response in the model may also reduce this problem, and may dampen the oscillatory dynamics described by McLean & Nowak (1992) .
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APPENDIX A. MEAN VALUE OF THE INHIBITORY EFFECT, s ( p )
For perfect adherence, · s is just the area under s(t) for one dosing interval, divided by the length of the interval T . We ¢nd that 
In solving this equation we have set t p in equation (1) ¡ log (C max e ¡iwT ‡ IC 50 ).
For the Poisson model of adherence described in the text, it is clear that P i ( p), the probability that i successive doses were missed after the last dose was taken, is given by p(1 ¡ p) i . Thus for this adherence pattern we can compute
In writing this equation we assume that no matter how small p is, a single dose was taken at time zero. (When pˆ0, we set · sˆ1.) We can use this equation to approximate · s 1 ( p) and · s 2 ( p) by using the appropriate values for drug-sensitive and drug-resistant IC 50 .
For the blocked model of adherence described in the text (and block-size n), we let P i ( p) be the probability that i successive blocks were missed after the last block of doses was taken, and simply de¢ne a block of doses taken as n successive doses, or a block of doses missed as n successive missed doses. In this case we ¢nd that P i ( p)ˆp (1 ¡ p) i as before, but now we de¢ne B i as the area under s(t) for a dosing block that occurs immediately after i blocks have been missed in succession.
It is clear that B 0ˆA0 , and for higher values of i we ¢nd
